<DOC>
	<DOC>NCT00092092</DOC>
	<brief_summary>The purpose of this study is to determine the effect of montelukast, an approved medication, on the lower leg growth rate in children with mild asthma. The primary hypothesis is that the lower leg length (LLL) growth rate for children treated with montelukast compared to placebo will be established.</brief_summary>
	<brief_title>Study of Montelukast and Its Effect on Lower Leg Growth in Children With Asthma (MK-0476-254)</brief_title>
	<detailed_description>This is a crossover study that consists of a 2-week placebo run-in period, then a first 3-week treatment period, then a 2-week washout period, and then a second 3-week treatment period. Participants will be randomized to treatment with either montelukast and placebo or budesonide and placebo. The duration of treatment is 6 weeks.</detailed_description>
	<mesh_term>Asthma</mesh_term>
	<mesh_term>Budesonide</mesh_term>
	<mesh_term>Montelukast</mesh_term>
	<criteria>A 6month history of asthma with periodic episodes requiring treatment. Medical history of a lung disorder (other than asthma) or a recent upper respiratory tract infection.</criteria>
	<gender>All</gender>
	<minimum_age>6 Years</minimum_age>
	<maximum_age>11 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>